Login to Your Account

Allicense 2013

Deloitte Recap Calls 2012 the 'Year of the Phase II'

By Catherine Shaffer
Staff Writer

Tuesday, April 30, 2013

SAN FRANCISCO – Phase II deal values surpassed Phase III in 2012, leading a senior biopharma analyst for Deloitte Recap LLC, to say "2012 was certainly the year of the Phase II" in her talk summarizing Deloitte's analysis of 1,692 deals closed in 2012 at the firm's Allicense Conference in San Francisco on Monday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription